Abstract
Introduction

Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of clonal plasma cells. Although novel agents, such as bortezomib and lenalidomide, have been developed for MM, it remains incurable. Plasma cell leukemia (PCL) is a rare MM variant, reported to occur in fewer than 5% of plasma cell neoplasms (1-4). Since PCL is highly aggressive and resistant to chemotherapy, its prognosis is very poor; median survival is reported to be 6-8 months (5). In this report, we describe a patient with primary PCL who has maintained complete remission (CR) for
F i g u r e 1 . Cl i n i c a l c o u r s e . T h e c l i n i c a l c o u r s e f o c u s i n g o n s y n g e n e i c S CT i s s h o wn . At y p i c a l c e l l s b e f o r e S CT c o r r e s p o n d wi t h p l a s ma c e l l s , wh e r e a s a t y p i c a l l y mp h o c y t e s a f t e r S CT ma y b e r e a c t i v e l y mp h o c y t e s r e s u l t i n g f r o m a v i r a l i n f e c t i o n .
Discussion
The effectiveness of autologous peripheral blood SCT for PCL has not been established. Saccaro et al reviewed 22 cases of PCL treated with stem-cell transplantation, including 5 allogeneic SCT cases (5). In their report, the mean survival of patients was 28 months. Since there was no significant difference of outcomes between allogeneic SCT and autologous SCT, the efficacy of allogeneic stem cell transplantation for PCL appeared to be limited. In this report, 5 out of 9 cases that underwent auto-SCT relapsed, suggesting that the PCL relapse rate after auto-SCT exceeds 50% (5). Therefore the most possible reason why the present case has maintained CR for more than three years is that the patient received SCT using a syngeneic graft that was free of myeloma, though it is possible that malignant cells were sensitive to melphalan. Gahrton et al reported the efficacy of a syngeneic peripheral blood SCT in multiple myeloma compared to autologous or allogeneic SCT (9). They showed a better overall survival (OS) in a syngeneic SCT (median 73 months) than in an autologous SCT (median 44 months) or an allogeneic SCT (median 16 months). Also, progression-free survival in the syngeneic SCT (median 72 months) was longer than that in an autologous SCT (median 25 months) or an allogeneic SCT (median 9 months
). An-other study, which compared the outcomes between syngeneic and autologous SCT for multiple myeloma, has recently been reported (10) 
